Kura Oncology is committed to discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. We focus on the development of small molecule drug candidates that target cell signaling pathways that are important to driving the progression of certain cancers. We aim to employ molecular diagnostics to identify patients with cancers who are likely to benefit from our targeted drug candidates.
Ongoing Clinical Trials
|Phase 2 clinical trial of Tipifarnib in patients with solid tumors with HRAS mutations||Learn More »|
|Phase 2 clinical trial of Tipifarnib in patients with relapsed or refractory PTCL||Learn More »|
|Phase 2 clinical trial of Tipifarnib in patients with transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)||Learn More »|
|Phase 2 clinical trial of Tipifarnib in patients with Chronic Myelomonocytic Leukemia||Learn More »|
|Investigator-sponsored Phase 2 clinical trial of Tipifarnib in patients with urothelial carcinoma tumors, characterized by HRAS mutations||Learn More »|
|Phase 1 clinical trial of KO-947 in patients with locally advanced unresectable or metastatic, relapsed and/or refractory non-hematological malignancies||Learn More »|
Tipifarnib and KO-947 are investigational drug candidates and have not yet been approved for use by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.